TWI233361B - Methods of preventing UVB-induced skin damage - Google Patents

Methods of preventing UVB-induced skin damage Download PDF

Info

Publication number
TWI233361B
TWI233361B TW091107218A TW91107218A TWI233361B TW I233361 B TWI233361 B TW I233361B TW 091107218 A TW091107218 A TW 091107218A TW 91107218 A TW91107218 A TW 91107218A TW I233361 B TWI233361 B TW I233361B
Authority
TW
Taiwan
Prior art keywords
tsp
skin
composition
cells
cell
Prior art date
Application number
TW091107218A
Other languages
English (en)
Chinese (zh)
Inventor
Michael J Detmar
Kiichiro Yano
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of TWI233361B publication Critical patent/TWI233361B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW091107218A 2001-04-13 2002-04-10 Methods of preventing UVB-induced skin damage TWI233361B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28387401P 2001-04-13 2001-04-13

Publications (1)

Publication Number Publication Date
TWI233361B true TWI233361B (en) 2005-06-01

Family

ID=23087934

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091107218A TWI233361B (en) 2001-04-13 2002-04-10 Methods of preventing UVB-induced skin damage

Country Status (8)

Country Link
US (1) US6712617B2 (cg-RX-API-DMAC7.html)
EP (1) EP1377253A4 (cg-RX-API-DMAC7.html)
JP (1) JP2004526758A (cg-RX-API-DMAC7.html)
KR (2) KR20040021598A (cg-RX-API-DMAC7.html)
CN (1) CN100340287C (cg-RX-API-DMAC7.html)
CA (1) CA2446093A1 (cg-RX-API-DMAC7.html)
TW (1) TWI233361B (cg-RX-API-DMAC7.html)
WO (1) WO2002083088A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266706A1 (en) * 2002-11-05 2004-12-30 Muthiah Manoharan Cross-linked oligomeric compounds and their use in gene modulation
TWI312681B (en) * 2001-02-01 2009-08-01 Novel physiologically active substance
TWI334866B (en) * 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
US7238370B2 (en) * 2002-06-14 2007-07-03 Rosenberg E William Method and composition to prevent and treat photoaging of skin
JP5122060B2 (ja) * 2002-06-25 2013-01-16 株式会社 資生堂 抗老化剤
US7256178B2 (en) * 2002-07-31 2007-08-14 Eisai Co., Ltd. Physiologically active substances
EP1541570A4 (en) * 2002-07-31 2008-05-21 Mercian Corp NEW PHYSIOLOGICALLY EFFECTIVE SUBSTANCE
US7458982B2 (en) 2002-10-04 2008-12-02 Photokinetix, Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
DE10254214A1 (de) * 2002-11-20 2004-06-09 Beiersdorf Ag Oligoribonukleotide zur Behandlung von degenerativen Hauterscheinungen durch RNA-Interferenz
RU2330069C2 (ru) * 2002-11-29 2008-07-27 Мершан Корпорейшн Способ получения макролидного соединения и штаммы streptomyces sp., mortierella sp. и micromonosporaceae
US20050281761A1 (en) * 2004-04-01 2005-12-22 Michael Detmar Methods of preventing UVB-induced skin damage
US20050276762A1 (en) * 2004-06-15 2005-12-15 Tapas Das Topical compositions containing 5'-adenosine-diphosphate ribose
US8795315B2 (en) * 2004-10-06 2014-08-05 Cook Medical Technologies Llc Emboli capturing device having a coil and method for capturing emboli
KR101160765B1 (ko) 2004-10-12 2012-06-28 어웨어, 인크. 트랜시버에서의 메모리 할당 방법
CA2607142C (en) * 2005-05-05 2014-03-25 Genencor International, Inc. Personal care compositions and methods for their use
EP1938827A4 (en) * 2005-09-16 2010-07-21 Shiseido Co Ltd NEW HEMMER OF THE EXPRESSION OF VASCULAR ENDOTHEL GROWTH FACTOR
DE602007008365D1 (de) 2006-01-18 2010-09-23 Gen Hospital Corp Verfahren zur steigerung der lymphatischen funktion
EP2005674B1 (en) 2006-04-12 2016-09-28 TQ Delta, LLC Packet retransmission and memory sharing
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
CA2659562A1 (en) * 2006-08-14 2008-02-21 Eisai R&D Management Co., Ltd. Stable lyophilized preparation
NZ575828A (en) * 2007-01-29 2011-04-29 Eisai R&D Man Co Ltd Solid of macrolide compound, method for production thereof, and pharmaceutical composition comprising the same
TW200918099A (en) 2007-09-14 2009-05-01 Nitto Denko Corp Drug carriers
US9132202B2 (en) 2009-07-17 2015-09-15 Aaron T. Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
EP2484359B1 (en) 2009-09-30 2018-07-25 Shiseido Company, Ltd. Heparanase activity inhibitor
JP2023512423A (ja) 2019-12-24 2023-03-27 ジュベナ・セラピューティクス・インコーポレイテッド 再生性ポリペプチドおよびその使用
WO2021133858A1 (en) * 2019-12-24 2021-07-01 Juvena Therapeutics, Inc. Heparin-associated polypeptides and uses thereof
CN117999278A (zh) 2021-06-21 2024-05-07 裘美娜治疗公司 再生性多肽及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025334A (en) * 1994-04-28 2000-02-15 Les Laboratoires Aeterna Inc. Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof
KR20010013047A (ko) * 1997-05-27 2001-02-26 존흐휴알. 기름체의 용도
US6372234B1 (en) * 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
AU1597199A (en) * 1997-11-25 1999-06-15 Cornell Research Foundation Inc. Methods and compositions for inhibiting hiv infectivity and blocking chemokine activity
KR20010105403A (ko) 1999-03-31 2001-11-28 마빈 씨. 구트리 트롬보스폰딘-2 및 이의 용도
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis

Also Published As

Publication number Publication date
CN1512868A (zh) 2004-07-14
WO2002083088A1 (en) 2002-10-24
US6712617B2 (en) 2004-03-30
EP1377253A4 (en) 2008-09-03
JP2004526758A (ja) 2004-09-02
EP1377253A1 (en) 2004-01-07
KR20080108366A (ko) 2008-12-12
KR20040021598A (ko) 2004-03-10
US20030008821A1 (en) 2003-01-09
CA2446093A1 (en) 2002-10-24
CN100340287C (zh) 2007-10-03

Similar Documents

Publication Publication Date Title
TWI233361B (en) Methods of preventing UVB-induced skin damage
DE69821011T2 (de) Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen
Wasterlain et al. Felbamate reduces hypoxic-ischemic brain damage in vivo
KR20080108530A (ko) 신경 쓰레드 단백질 기초 펩티드를 사용하여 암 위험 또는 발병을 예방 또는 감소시키는 방법
HUE035074T2 (en) Alpha-MSH derivatives for the treatment of photodermatoses
EP3856228A1 (en) Methods and pharmaceutical composition reducing skin inflammation
JP2006521405A (ja) 発作回復におけるエリトロポイエチンの使用
US20050276765A1 (en) Preventing skin damage
Wang et al. Effects of delayed treatment with transforming growth factor-β soluble receptor in a three-dose bleomycin model of lung fibrosis in hamsters
EP1131087B1 (en) Methods of alleviating cancer symptoms
US10857199B2 (en) Compounds and methods for increasing hair growth
US8133491B1 (en) Compositions and methods for treatment of hyperplastic disorders
US20230364192A1 (en) Modulation of beta cell regeneration through gpr75 signaling
US20210213137A1 (en) Compositions to treat ultraviolet (uv)-induced skin injury
EP4121080A1 (en) Molecular transport system to the central nervous system
Elgendy Comparison between local application of doxycycline loaded nanoparticles and conventional doxycycline gel on matrix metalloproteinase 1 and bone density in chronic periodontitis
Desai et al. Noncanonical Nf-κB Activation by Icariin-Triggered CEBP-β/G-CSF Axis Confers Neuroprotection in Ischemic Optic Neuropathy
Esteban Pyrrole-imidazole polyamide-H promotes anti-inflammation during the acute phase of spinal cord injury
Mehina Investigating the deleterious effects of type 1 diabetes mellitus on microvascular repair in the mouse cortex
CN118806788A (zh) 活性氧在预防和/或治疗纤维化及与纤维化明确相关的疾病中的用途
JP2022532306A (ja) フェキサポチドトリフルタートを用いた下部尿路症状の治療効果を高める方法
HK1066173A (en) Methods of alleviating cancer symtoms
CN111588854A (zh) Trf2或其上调剂在制备治疗肌肉疾病的药物中的应用
Weller et al. Eosinophils from patients with blood eosinophilia express
Sinn et al. Albumin-Based Drug Delivery as Novel

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent